Artur Rycyk

Dr. Artur Rycyk

Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, Poland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ARArtur Rycyk
Artur Rycyk
BCBeata Cudowska
Beata Cudowska
DLDariusz M. Lebensztejn
Dariusz M. Lebensztejn
Diagnosis of non-IgE mediated food allergy presents a special challenge due to lack of a single, non-invasive diagnostic method. We selected three fecal biomarkers of allergic inflammation of gastrointestinal origin in order to improve the diagnostic process. Twenty-seven infants with symptoms of hematochezia were prospectively enrolled into this study. All patients underwent a complete differential diagnosis of rectal bleeding. Non-IgE mediated food allergy was confirmed by an open, oral food challenge. The control group included twenty-five infants with functional gastrointestinal disorders. Eosinophil-derived neurotoxin (EDN), tumor necrosis factor alpha (TNFα), and calprotectin concentration were measured in stools of all children by enzyme-linked immunosorbent assays (ELISA) using commercial kits. Median eosinophil-derived neurotoxin and calprotectin fecal levels were significantly higher in the study group than in the control group (p < 0.05). The difference of fecal tumor necrosis factor alpha concentration between both groups was not statistically significant (p > 0.05). The best diagnostic performance was reached in a combination of fecal calprotectin (fCal) and EDN i.e., 88.9% and 84%, respectively. Fecal EDN and fCAl are reliable tools in differentiating between food protein-induced allergic proctocolitis and gastrointestinal functional disorders in infants.

23 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KZKatarzyna Zdanowicz
Katarzyna Zdanowicz
ARArtur Rycyk
Artur Rycyk
DLDariusz Marek Lebensztejn
Dariusz Marek Lebensztejn
UDUrszula Daniluk
Urszula Daniluk
Background/Objectives: In recent years, there has been an increase in the prevalence of eosinophilic esophagitis (EoE), in which dysphagia is one of the main symptoms. To date, there are few data on the prevalence of EoE in pediatric patients with dysphagia. The aim of this study was to determine the causes of dysphagia in children in our region. The second aim of this study was to estimate the prevalence of EoE in children with swallowing difficulties and to see if there were differences in the characteristics of dysphagia reported by children with EoE compared to children with non-EoE-related dysphagia. Methods: The 6-year retrospective analysis included patients with dysphagia who were referred to our department. Children with dysphagia were further divided into two groups: group I consisted of children with dysphagia due to EoE, while group II consisted of children with dysphagia due to other causes (non-EoE). Results: One hundred and forty-six children between the ages 0 and 17 were enrolled into the study, including thirty-seven in group I and one hundred and nine in group II. The most common causes of dysphagia were gastrointestinal diseases, followed by neurological/psychiatric disorders. The prevalence of EoE was 25.34% in the whole study group and 41.11% considering only gastrointestinal causes of dysphagia. Children in group I were more likely to have coexisting asthma, allergic rhinitis and food allergy. There was statistically significance in higher blood eosinophil count in EoE individuals. In a multivariate binominal logistic regression model, only eosinophilia and coexisting food allergy were associated with an increased risk of EoE in patients with dysphagia. Conclusions: In our study, the most common cause of dysphagia was gastroenterological diseases, especially EoE. Patients with dysphagia, comorbid allergy and peripheral blood eosinophilia should be suspected for having EoE and referred for endoscopy.

23 June 2025 in Archives of Medical Science
Verified
Journal Article
Open access
KZKatarzyna Zdanowicz
Katarzyna Zdanowicz
ACAleksandra Czajkowska
Aleksandra Czajkowska
ARArtur Rycyk
Artur Rycyk
DLDariusz Marek Lebensztejn
Dariusz Marek Lebensztejn
UDUrszula Daniluk
Urszula Daniluk
Introduction: Personalized medicine in inflammatory bowel disease (IBD) aims to achieve maximum effectiveness through rapid induction and maintenance of remission. To achieve this goal, reliable predictors of disease course are needed. The aim of this study was to identify early markers of IBD's poor course understood as the need for anti-tumor necrosis factor (anti-TNFα) treatment.Material and methods: We analyzed the clinical, laboratory, radiological and endoscopic data of children with IBD. These parameters were assessed at the time of diagnosis (T0) and 8-12 weeks (T1) after the start of induction therapy. The results of patients who did not require anti-TNFα treatment were compared to children who needed such treatment during the 2-year observation time.Results: 58.14% of patients with Crohn's disease (CD) and 31.71% of patients with ulcerative colitis (UC) required biological therapy. Patients with CD and UC receiving biological therapy, compared with those without, differed in selected clinical and laboratory parameters both at T0 and T1. In multivariate analysis, the risk of anti-TNFα therapy in patients with CD was associated with the lack of normalization of MCV and PCDAI. In patients with UC higher albumin levels reduced this risk.Conclusions: In children with IBD, disease activity and concentrations of selected biochemical parameters assessed within 3 months after diagnosis may be helpful in predicting a poor outcome of CD and UC.